# MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

> **NCT04651634** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MitoImmune Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Oral Mucositis

## Interventions

- **DRUG:** MIT-001 plus CCRT

## Key facts

- **NCT ID:** NCT04651634
- **Lead sponsor:** MitoImmune Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-21
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04651634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04651634, "MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04651634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*